Am Fedfunds Usd (FEDF) Share Price

I'm thinking you all who own a shite ton of this stock better pay attention to what Shawn Leon has been saying about the New York Stock Exchange uplist since the podcast at the beginning of January. It isn't about actually being qualified for the NYSE in my opinion but rather it is a justification f

Good morning Larry, hope we see some rain around here this week. It's getting mighty dry.

" Capgain, Guud Morning " ... !!

Interesting qualifier ".0003 and under".

Why not ask him at any price? Since ERHC has traded as high as .005 since it's been on the greys?

Krombacher

Seems like she's a major part of the problem.

jmo.

Kitty will post on X today that he has exited $GME . Single digit by end of day

I'm positive on Amazon! Are you dense?

Triple...Great good news...Now we await important forthcoming announcements from Edding about reimbursements for Vascepa...as they talk with the NMPA (Chinese National Products Administration)....These developments could influence Vascepa prices worldwide and lead to an explosive growth in sales v

SURPRISED IT"S STAYED ABOVE .01 THIS LONG. That's the fixed price for the Auctus dilution which will continue until SEPT when the last of their toxic loan shares matures. So it may stay above .01 till then. The lease at FAU expires first of the year so. They won't last after that.

GIFA TRUTH IS IN FILINGS, DRAGON LIES (YAWN)

Not difficult to understand Jurisdiction while some others just CAN"T

https://investorshub.advfn.com/uimage/uploads/2024/7/8/kepxgScreenshot_2024-07-08_5.17.52_AM.png

The trial showed absolute superiority of Medivand's product over Santyl in terms of the percentage of cases that reached complete wound healing during the first two weeks of treatment (63% vs. 0%); The median time for complete healing of the wound (nine days compared to not reaching complete healing

Medivend, which developed a product for healing wounds, became an attractive target for acquisition
A successful trial of the flagship product that showed superiority over the leading product for healing chronic wounds, fundamental changes in insurance policy in the US and the product's succe

Medivend, which developed a product for healing wounds, became an attractive target for acquisition

A successful trial of the flagship product that showed superiority over the leading product for healing chronic wounds, fundamental changes in insurance policy in the US and the product

Well, here we go. Another new week, but now this ticker has the EM hanging over it's head, with the yield sign ready to be stripped away. And, based on this tickers lack of fins & information...it seems imminent.
Not a good thing, while others think it's no big deal.
Come on CEO...put

$RNVA==>$FOXO ===>NYSE====>KAPOW POW $$$$ gooood morning!

Ok, keep responding, it proves I am correct. Tic toc tic toc

Old Holcombs Fraud trial isn’t going well for the scammer Holcomb. The judge refused to dismiss it after his defence of “I never said it works”. Bwahaaaaaaaaa

Great find. Maybe they don’t want to affect the SP while undertaking share buyback, but if it’s material they only have a set number of days to announce. There haven’t been any SEC filings since approval. I presume there will be a milestone payment due which will be welcome in Q3.

So r m reversed ???????

Neat share structure

Shareholders post

Terrible what happened here

$000

If debt free stock price will be interesting where headed